View Author
stent patient follow-up month study 6 months lesion strut trial scaffold analysis 2 years vessel artery result spirit everolimu plaque ultrasound lumen change implantation event intravascular serruy signi everolimus-eluting stent thrombosis target intervention tissue table artery lesions death value outcome procedure hyperechogenicity echogenicity 3- year follow-up imaging treatment segment scaffold area serruys pw xience thrombosis randomized method diameter circulation drug-eluting spirit ii stent system swets subs service bioabsorbable intravascular ultrasound ficant figure 6- month follow-up lumen area angiography paclitaxel-eluting infarction reduction angiographic point process device luminal coherence tomography luminal area signi ficantly spirit ii trial revascularization measurement image stenosi 3 years cohort
10 Most Recent Publications
|
Serial in vivo intravascular ultrasound-based echogenicity changes of everolimus-eluting bioresorbable vascular scaffold during the first 12 months after implantation: Insights from the ABSORB B trial
(Article)
Brugaletta, S. Gomez-Lara, J. Windecker, S. Smits, P.C. Bruyne, B. de Whitbourn, R. Meredith, I. Domburg, R.T. van Sihan, K. Winter, S. de Veldhof, S. Miquel-Hébert, K. Serruys, P.W.J.C. Rapoza, R. Garcia-Garcia, H.M. Ormiston, J.A. Bruining, N. Farooq, V. Geuns, R-J.M. van Thuesen, L. Dudek, D. Koolen, J. Chevalier, B. McClean, D. |
2011-12-01
|
|
Four-year clinical follow-up of the XIENCE v everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: The SPIRIT II trial
(Article)
Garg, S.A. Serruys, P.W.J.C. Miquel-Hébert, K. |
2011-06-01
|
|
Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents: A pooled analysis from the SPIRIT II (A Clinical Evaluation of the XIENCE v Everolimus Eluting Coronary Stent System in the Treatment of Patients with de Novo Native Coronary Artery Lesions) and SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE v Everolimus Eluting Coronary Stent System [EECSS]
(Article)
Caixeta, A. Lansky, A.J. Sood, P. Su, X. Jonnavithula, L. Sudhir, K. Stone, G.W. Serruys, P.W.J.C. Hermiller, J.B. Ruygrok, P.N. Onuma, Y. Gordon, P. Yaqub, M. Miquel-Hébert, K. Veldhof, S. |
2010-12-01
|
|
Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: Six-month clinical and imaging outcomes
(Article)
Serruys, P.W.J.C. Onuma, Y. Koolen, J. Windecker, S. Whitbourn, R. Meredith, I. Dorange, C. Veldhof, S. Miquel-Hébert, K. Rapoza, R. Garcia-Garcia, H.M. Ormiston, J.A. Bruyne, B. de Regar, E.S. Dudek, D. Thuesen, L. Smits, P.C. Chevalier, B. McClean, D. |
2010-11-30
|
|
Temporal changes of coronary artery plaque located behind the struts of the everolimus eluting bioresorbable vascular scaffold
(Article)
Brugaletta, S. Garcia-Garcia, H.M. Chevalier, B. Windecker, S. Whitbourn, R. Dorange, C. Miquel-Hébert, K. Sudhir, K. Ormiston, J.A. Serruys, P.W.J.C. Garg, S.A. Gomez-Lara, J. Diletti, R. Onuma, Y. Geuns, R-J.M. van McClean, D. Dudek, D. Thuesen, L. |
2010-10-13
|
|
Five-year long-term clinical follow-up of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: The SPIRIT FIRST trial
(Article)
Wiemer, M. Serruys, P.W.J.C. Miquel-Hébert, K. Neumann, F.J. Piek, J.J. Grube, E. Haase, J. Thuesen, L. Hamm, C.W. |
2010-06-01
|
|
Monitoring in vivo absorption of a drug-eluting bioabsorbable stent with intravascular ultrasound-derived parameters: A feasibility study
(Article)
Bruining, N. Winter, S. de Thuesen, L. Ormiston, J.A. Cheong, W.F. Miquel-Hébert, K. Veldhof, S. Serruys, P.W.J.C. Roelandt, J.R.T.C. Regar, E.S. Heller, I. Domburg, R.T. van Hamers, R. Onuma, Y. Dudek, D. Webster, M.W.I. |
2010-03-01
|
|
3-Year Clinical Follow-Up of the XIENCE V Everolimus-Eluting Coronary Stent System in the Treatment of Patients With De Novo Coronary Artery Lesions. The SPIRIT II Trial (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions)
(Article)
Garg, S.A. Serruys, P.W.J.C. Riele, J.A. te Onuma, Y. Dorange, C. Veldhof, S. Miquel-Hébert, K. Sudhir, K. Boland, J.B. Huber, K. Garcia, E. |
2009-12-01
|
|
A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods
(Article)
Serruys, P.W.J.C. Ormiston, J.A. Veldhof, S. Webster, M. Thuesen, L. Dudek, D. Onuma, Y. Regar, E.S. Gonzalo, N. Garcia-Garcia, H.M. Nieman, K. Bruining, N. Dorange, C. Miquel-Hébert, K. |
2009-03-18
|
|
Systemic exposure of everolimus after stent implantation: A pharmacokinetic study
(Article)
Wiemer, M. Seth, A. Roeck, K. de Serruys, P.W.J.C. Chandra, P. Neuzner, J. Richardt, G. Piek, J.J. Desaga, M. Macaya, C. Bol, C.J. Miquel-Hébert, K. |
2008-10-01
|
